Evidence map›Paper›PMID 39740515›Full record

ArticleTranslational oncology2025

Wilms tumor primary cultures capture phenotypic heterogeneity and facilitate preclinical screening.

Lisa Götz, Jenny Wegert, Alireza Paikari, Silke Appenzeller, Sabrina Bausenwein, Christian Vokuhl, Taryn D Treger, Jarno Drost, Christin Linderkamp, Dominik T Schneider and 8 more

Abstract read
In one paragraph

Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Lisa GötzTheodor-Boveri-Institute/Biocenter, Developmental Biochemistry, Julius-Maximilians-University Würzburg, Würzburg, Germany.
Jenny WegertTheodor-Boveri-Institute/Biocenter, Developmental Biochemistry, Julius-Maximilians-University Würzburg, Würzburg, Germany.
Alireza PaikariTheodor-Boveri-Institute/Biocenter, Developmental Biochemistry, Julius-Maximilians-University Würzburg, Würzburg, Germany.
Silke AppenzellerComprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany.
Sabrina BausenweinTheodor-Boveri-Institute/Biocenter, Developmental Biochemistry, Julius-Maximilians-University Würzburg, Würzburg, Germany.
Christian VokuhlSection of Pediatric Pathology, Department of Pathology, University Hospital Bonn, Bonn, Germany.
Taryn D TregerWellcome Sanger Institute, Hinxton, UK; Department of Pediatrics, University of Cambridge, Cambridge CB2 0QQ, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Jarno DrostPrincess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Christin LinderkampDepartment of Pediatric Hematology and Oncology, Hannover Medical School (MHH), Hannover, Germany.
Dominik T SchneiderClinic of Pediatrics, Klinikum Dortmund, University Witten/Herdecke, Germany.
Karen ErnestusComprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany; Department of Pathology, University of Würzburg, Würzburg, Germany.
Steven W WarmanClinic of Pediatric Surgery, Charité - University Hospital Berlin, Berlin, Germany; Department of Pediatric Surgery and Pediatric Urology, University Children's Hospital, Tuebingen, Germany.
Jörg FuchsDepartment of Pediatric Surgery and Pediatric Urology, University Children's Hospital, Tuebingen, Germany.
Nils WelterDepartment of Pediatric Hematology and Oncology, Saarland University Hospital, Homburg, Germany.
Norbert GrafDepartment of Pediatric Hematology and Oncology, Saarland University Hospital, Homburg, Germany.
Sam BehjatiWellcome Sanger Institute, Hinxton, UK; Department of Pediatrics, University of Cambridge, Cambridge CB2 0QQ, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Rhoikos FurtwänglerDepartment of Pediatric Hematology and Oncology, Saarland University Hospital, Homburg, Germany; Pediatric Hematology and Oncology, Dep. of Pediatrics, Bern University Hospital, University of Bern, Inselspital, Switzerland.
Manfred GesslerTheodor-Boveri-Institute/Biocenter, Developmental Biochemistry, Julius-Maximilians-University Würzburg, Würzburg, Germany; Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, Germany. Electronic address: manfred.gessler@uni-wuerzburg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wilms tumors (WT) are characterized by variable contributions of blastemal, epithelial and stromal elements, reflecting their diverse cellular origins and genetic drivers. In vitro models remain rare, despite a growing need to better characterize tumor biology and evaluate new treatments. Using three approaches, we have now established a large collection of long-term cultures that represent this diversity. Adherent WT cultures are predominated by stromal cells, 3D spheroids model blastema, and patient-derived organoid cultures of both tumor and healthy kidney tissue result in the preferential growth of epithelial cells. Adherent, spheroid and organoid cultures are also clearly distinguishable by their transcriptome. Preclinical drug screening experiments revealed sensitivity to a range of inhibitors, that are highly effective in other childhood solid tumors. Sensitivity was related to MYCN status, a marker associated with adverse outcome across human cancers including WT. The combination of the three culture techniques represents a promising tool to both explore tumor heterogeneity in vitro and to facilitate characterization of candidate driver genes, in order to improve treatment regimens in the future.

Indexed as

Drug screeningMYCNNephroblastomaOrganoid cultureWilms tumor

Identifiers

PMID39740515
PMCPMC11750297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.